	US 11,952,405 B2
	Agents and methods for treating CBP-dependent cancers
Alex Kentsis, New York, NY (US); Kavitha Ramaswamy, New York, NY (US); and Lauren Marek, New York, NY (US)
Assigned to MEMORAL SLOAN KETTERING CANCER CENTER, New York, NY (US)
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed on Nov. 29, 2021, as Appl. No. 17/536,296.
Application 17/536,296 is a continuation of application No. 16/346,834, granted, now 11,208,446, previously published as PCT/US2017/059579, filed on Nov. 1, 2017.
Claims priority of provisional application 62/415,800, filed on Nov. 1, 2016.
Prior Publication US 2022/0144907 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); A61P 35/02 (2006.01)

CPC C07K 14/4705 (2013.01) [A61P 35/02 (2018.01); A61K 38/00 (2013.01); C07K 2319/10 (2013.01)]

7 Claims

1. A method for treating leukemia, lymphoma, colon cancer, breast cancer, adenoid cystic carcinoma, brain cancer or a dysproliferative disease associated with a MYB dysregulation in a patient in need thereof, wherein the method comprises administering to said patient a therapeutically effective amount of a single chain peptide consisting of D-amino acids and comprising: an N-terminal portion comprising the amino acid sequence selected from KLENETSMLLLELEKIRK (SEQ ID NO:19) and KLENETSMLLLEL (SEQ ID NO:24); a C-terminal portion comprising the amino acid sequence RRRQRRKKRGY (SEQ ID NO:17); and the amino acid sequence therebetween selected from PADSSLDNLIKRYpSPRRSLIERR (SEQ ID NO:33), KRYpSPRRSLIERR (SEQ ID NO:23), and PADSSLDNLIKRYpS (SEQ ID NO:34).